TCGA-AO-A1KR-01A-12R-A144-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 84
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.550
- E2F_TARGETS+0.380
- MYC_TARGETS_V1+0.320
- SPERMATOGENESIS+0.220
- INTERFERON_ALPHA_RESPONSE+0.210
- KRAS_SIGNALING_DN+0.190
- OXIDATIVE_PHOSPHORYLATION+0.190
- G2M_CHECKPOINT+0.170
- UV_RESPONSE_UP+0.160
- DNA_REPAIR+0.100
Top 10 suppressed
- PROTEIN_SECRETION-0.520
- UV_RESPONSE_DN-0.480
- ANDROGEN_RESPONSE-0.400
- TGF_BETA_SIGNALING-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- MITOTIC_SPINDLE-0.310
- ESTROGEN_RESPONSE_EARLY-0.300
- ANGIOGENESIS-0.290
- HEME_METABOLISM-0.280
- APICAL_JUNCTION-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518141 | — | E | 0.844 |
| 2 | TCGA-BH-A0B9-01A-11R-A056-07 | — | E | 0.824 |
| 3 | FFAA0A2D-49B7-4491-9B22-C82CCF1501D0 | — | — | 0.814 |
| 4 | SRR650177 | — | — | 0.811 |
| 5 | 412859bb-8b2a-44bf-b3b2-6acd30986067 | — | — | 0.806 |
| 6 | TCGA-HN-A2NL-01A-11R-A18M-07 | — | E | 0.806 |
| 7 | TCGA-E9-A22G-01A-11R-A157-07 | — | E | 0.804 |
| 8 | TCGA-NC-A5HL-01A-11R-A26W-07 | — | cohortSQ2 | 0.803 |
| 9 | SRR650176 | — | — | 0.796 |
| 10 | TCGA-58-8387-01A-11R-2296-07 | — | cohortSQ2 | 0.795 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.550 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.070 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.070 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |
| HYPOXIA | 0.050 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.040 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.030 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.020 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.010 | Idelalisib | — uncovered |